Background: Several studies suggest that neuraminidase inhibitors (NIs) can reduce the duration of influenza symptoms. However, data regarding their effectiveness in reducing influenza complications are scarce.
Introduction
Influenza is an infection with a clinical picture varying from mild systemic symptomatology to respiratory failure and death. 1 Deaths in seasonal influenza occur mainly in young children and elderly individuals, whereas during influenza pandemics, 2 younger individuals seem to be affected disproportionately, particularly in the early stages of the pandemic. 3, 4 Historically, influenza viruses have caused global pandemics such as the Spanish pandemic of 1918 and the Asian flu of 1957. Recently, we encountered a pandemic caused by the A H1N1 pandemic influenza virus.
Yearly reports on seasonal influenza in the USA also provide estimations of 200 000 hospitalizations due to influenza-related complications and 36 000 influenza-related deaths. 5 -7 Vaccines and neuraminidase inhibitors (NIs) are the main preventive measures against influenza. A recent meta-analysis showed that the prophylactic use of NIs had no effect against influenza-like illness or asymptomatic influenza. However, oral oseltamivir and inhaled zanamivir were effective against laboratory-confirmed influenza, when used for prophylaxis. 8 The treatment armamentarium for influenza infection is limited to NIs because of the rapid emergence of resistance to adamantanes observed during the latest influenza epidemics. 9 Although a considerable number of trials indicate the effectiveness of NIs in reducing the severity and the length of the course of influenza illness, there is only scarce evidence verifying their impact on preventing serious complications and mortality of influenza. 10 -14 We aimed to evaluate the effectiveness of NIs, used for treatment of influenza, in reducing influenza complications, by performing a meta-analysis of relevant randomized controlled trials (RCTs).
Methods

Data sources
All clinical trials included in this meta-analysis were retrieved from PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and Scopus databases. These databases were last accessed in September 2009. A lower time limit for the literature search was not applied. Bibliographies of articles eligible and not eligible for inclusion were also hand searched. Articles published in languages other than English, French, Italian, German or Spanish, abstracts presented at scientific conferences, unpublished studies and other unpublished data deriving from industry sites were not included. The search strategy applied to the PubMed database was '(oseltamivir OR zanamivir OR antivirals) AND (influenza OR flu) AND (complications OR pneumonia OR otitis OR mortality OR death)'. The key words applied to Cochrane CENTRAL were 'zanamivir' and 'oseltamivir', whereas the search strategy applied to the Scopus database was '(antivirals OR oseltamivir OR zanamivir) AND (complications OR pneumonia OR otitis OR mortality OR death)'.
Study selection process
Two reviewers (P. K. K. and E. K. V.) independently performed the literature search, assessed the potential eligibility of the retrieved studies and extracted the data. Studies were considered eligible for inclusion in the meta-analysis if they represented an RCT that enrolled patients of any age or health status with influenza or influenza-like syndrome and were randomized to receive either antiviral treatment (NIs) or placebo. Additionally, the trials should have provided data regarding any influenza complication.
Data extraction
Data extracted from each of the trials included in this meta-analysis consisted of the study design, quality assessment, characteristics of the study populations, laboratory method used for confirmation of the influenza infection, characteristics of compared treatment arms and potential concomitant treatment, the types of influenza complications and adverse events evaluated, the intention to treat (ITT) population and the subgroup of patients with laboratory-confirmed influenza infection, the timepoints of follow-up assessments, as well as data regarding the effectiveness and safety outcomes of our meta-analysis. Only patientrelated data were included.
Definitions and outcomes
Influenza or influenza-like illness was defined by the presence of fever (≥37.88C) and more than two of the following symptoms: sore throat, cough, headache, muscle or joint aches and pains. The ITT population included all patients randomized to receive the respective study regimens. The influenza-confirmed population included patients with laboratory-confirmed influenza. High-risk patients were patients with chronic respiratory disease (asthma, chronic obstructive pulmonary disease) requiring regular medication, or chronic cardiac disease (excluding hypertension), immunocompromised or elderly individuals (age .65 years).
Effectiveness outcomes
Total influenza-related complications, defined as any complication of respiratory origin (such as pneumonia, bronchitis, asthma exacerbations, otitis media, sinusitis and pharyngitis), occurring at any time during the study, considered by the authors of each individual study as related to the influenza infection, were considered as the primary effectiveness outcome of this meta-analysis. The following influenza-related complications were also evaluated as individual effectiveness outcomes: pneumonia, bronchitis, asthma exacerbations, sinusitis, pharyngitis/tonsillitis, acute otitis media and mortality. Secondary effectiveness outcomes included the number of patients that needed antibiotic treatment (antibiotic use may be regarded as a poor surrogate indicator of bacterial infection) and hospitalizations occurring at any time and for any cause during the study period. All effectiveness outcomes were assessed on the subpopulation of patients with confirmed influenza infection.
Safety outcomes
The safety outcomes of our meta-analysis included adverse events, defined as total drug-related adverse events reported during the study period, along with specific common types of adverse events such as diarrhoea and nausea/vomiting, as well as study withdrawals due to adverse events. The safety outcomes were assessed on the ITT population. In cases where such data were not available, we used the respective data regarding patients with laboratory-confirmed influenza infection.
Subgroup and sensitivity analysis
The primary effectiveness outcome was evaluated in two separate subgroup analyses, regarding otherwise healthy patients and high-risk patients with laboratory-confirmed influenza, respectively. We also tested for differences between these subgroups of trials. We performed a sensitivity analysis to evaluate the primary effectiveness outcome in trials comparing zanamivir treatment with placebo, as well as in trials comparing oseltamivir treatment with placebo, and we tested for differences between these subgroups of trials. In a second sensitivity analysis we evaluated the primary effectiveness outcome in trials involving paediatric populations, as well as in trials involving adult populations, and we tested for subgroup differences.
Quality assessment
The Jadad score was used for the assessment of the methodological quality of the trials included in our meta-analysis. The presence of randomization, blinded design and information regarding study withdrawals are parameters evaluated by the Jadad criteria. The appropriateness of randomization and blinding procedures, if present, was also evaluated. Specifically, one point is awarded for the presence of each of the first three parameters. In contrast, each of the latter two parameters is awarded the values of 21 (when regarded as inappropriate) and +1 (when regarded as appropriate). The maximum attributable score with the use of the Jadad score was 5 points. A score .2 points denoted a trial with an adequate methodological quality. 15, 16 
Statistical analysis
We estimated pooled risk ratios (RRs) and the respective 95% confidence intervals (CIs) for the analysed outcomes using a random effects 
Results
Our searches generated a total of 2299 articles (1164 from PubMed, 1032 from Scopus and 103 from Cochrane CENTRAL). Of these, 11 RCTs were eligible for inclusion. 18 -28 Figure 1 depicts in detail the process used for the selection of trials.
Study characteristics
Ten of the 11 included trials were double-blind, multicentre RCTs, whereas the remaining 1 was an open-label multicentre RCT. 24 All of the included trials were assigned a Jadad score .2. Specifically, five trials were assigned a Jadad score of 5, 19 -22,28 three a score of 4 18, 26, 27 and the remaining three a score of 3. 23 -25 In 6 of the 11 included trials, patients were randomized to receive either zanamivir or placebo, 18 -23 whereas in the remaining 5, patients received either oseltamivir or placebo. 24 -28 One zanamivir trial 23 and two oseltamivir trials 27, 28 had two antiviral treatment arms. Details regarding the route of administration, the dosages and the durations of the evaluated treatment regimens are presented in Table 1 . Additionally, specific data regarding the method used for confirmation of the influenza infection, concomitant treatment, the types of complications and adverse events evaluated, the ITT population and the subgroup of the included patients with confirmed influenza infection, as well as the timepoints of follow-up assessment in each one of the included studies, are presented in Table 1 Figure 1 . Flow diagram of the detailed process of selection of trials for inclusion in the meta-analysis.
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Patient characteristics
A total of 5315 patients were included in the 11 analysed trials. From these, 3491 (65.7%) had confirmed influenza infection. The proportion of patients with confirmed influenza infection ranged between 47.5% and 78% among the included trials. A viral culture along with serology was used for the laboratory confirmation of the influenza infection in all except one of the included trials. 22 Eight of the 11 included trials involved adult and adolescent (.12 years) patients, 18,20 -24,27,28 whereas the remaining 3 studies involved children (the age distributions of the included children ranged between 1 and 12 years in these 3 trials). 19, 25, 26 All except 3 of the 11 included trials involved previously healthy populations. Specifically, two of these three studies enrolled adult patients with underlying respiratory disease (such as asthma and chronic obstructive pulmonary disease) 20, 24 or coronary heart disease. 24 The remaining study involved children with severe asthma. 25 
Outcomes
Data extracted from each of the trials included in our metaanalysis are presented in tabulated form in Table 2 . These data were incorporated in the analyses performed regarding the effectiveness and safety outcomes of our meta-analysis. We present the respective findings below.
Effectiveness outcomes
Total influenza-related complications were significantly less likely in otherwise healthy patients with confirmed influenza infection that were treated with NIs versus placebo [7 RCTs, 2621 patients, RR¼ 0.74, 95% CI ¼ 0.58 -0.95, Figure 2] . 18,19,21,23,26 -28 This finding was consistent in the analysis regarding high-risk patients included in the respective evaluated studies [4 RCTs (3 providing data for patients with laboratory-confirmed infection 20,21,24 and 1 for a mixed population with a majority of patients with laboratory-confirmed infection 22 ), 475 patients, RR¼0.37, 95% CI ¼ 0.24-0.59, Figure 2] . 20 -22,24 After excluding the open-label study from the latter analysis, a moderate change in the results was observed (3 RCTs, 419 patients, RR¼ 0.41, 95% CI ¼ 0.25-0.67).
16 -18 When we tested for subgroup differences, the effectiveness of NIs in reducing total influenza-related complications was more pronounced in high-risk patients compared with otherwise healthy patients (P,0.01 for the x 2 test for subgroup differences).
Regarding pneumonia and bronchitis, no difference was found between patients with confirmed influenza infection treated with NIs versus patients treated with placebo (3 RCTs, 1309 patients, RR¼ 0.56, 95% CI ¼ 0.10-3.16, Figure 3; 26 -28 and 2 RCTs, 849 patients, RR¼ 0.83, 95% CI¼ 0.23 -3.01, 27,28 respectively). Regarding pneumonia in particular, due to the small numerators observed, Peto's method was used as an alternative in order to calculate pooled risk ratios. 29 However, no difference was observed between the compared groups. Acute otitis media was significantly less likely in patients with confirmed influenza infection treated with NIs versus placebo (3 RCTs, 1124 patients, RR¼ 0.50, 95% CI ¼ 0.30 -0.85). 26 -28 The difference found between patients with confirmed influenza infection treated with NIs versus placebo was not 24 -26 No difference was found regarding additional antibiotic treatment in the number of patients with confirmed influenza infection treated with NIs in comparison with patients that received placebo (6 RCTs, 1921 patients, RR¼ 0.79, 95% CI ¼ 0.61-1.02, Figure 4) . 18, 19, 23, 24, 26, 28 No adequate data for patients with confirmed influenza regarding the remaining effectiveness outcomes, i.e. asthma exacerbations and pharyngitis/tonsillitis, were available in order to perform a meta-analysis for these specific outcomes. Four of the 11 included studies provided mortality data. No deaths occurred in patients assigned to either the respective NIs or placebo treatment arms. 20, 25, 26, 28 Regarding the first sensitivity analysis, total influenza-related complications were significantly less likely in patients treated with oseltamivir versus those treated with placebo (4 RCTs, 1096 patients, RR¼0.62, 95% CI ¼0.45 -0.85, Figure 5 ), 24,26 -28 whereas no difference was found between patients treated with zanamivir and those treated with placebo (5 RCTs, 1633 patients, RR¼ 0.76, 95% CI ¼0.57 -1.02, Figure 5) ; 18 -21,24,26 -28 P ¼ 0.003 for the x 2 test for subgroup differences. In the second sensitivity analysis, no difference regarding total influenza-related complications was observed between trials involving paediatric populations and trials involving adult populations (2 RCTs, 798 patients, RR¼ 0.63, 95% CI ¼ 0.48-0.84, 19, 26 Figure 6 ; versus 7 RCTs, 2192 patients, RR¼0.68, 95% CI ¼ 0.48-0.96, Figure 6 , 18, 20, 21, 23, 24, 27, 28 respectively; P¼ 0.05 for the x 2 test for subgroup differences).
Safety outcomes
No difference was found in the occurrence of total drug-related adverse events between patients treated with NIs and those who received placebo (4 RCTs, 1594 patients, RR¼ (Figure 7 ). Regarding study withdrawals due to adverse events, no difference was found between patients treated with NIs versus those that received placebo (11 RCTs, 5064 patients, RR¼ 1.38, 95% CI ¼ 0.64-2.98).
-28
Discussion
The main finding of our study is that total influenza-related complications were less likely in otherwise healthy patients with confirmed influenza treated with NIs versus those treated with placebo. This finding was more pronounced in high-risk patients and also consistent in the sensitivity analyses limited to paediatric and adult trials, respectively. In the analyses regarding individual respiratory influenza complications a trend in favour of NIs was observed. However, the observed differences were not significant. This may be attributed to the limited number of trials included in the respective comparisons. However, acute otitis media was less frequent in patients treated with NIs [the Regarding pneumonia, a trend in favour of NIs was observed (NNT ¼333 patients, with a risk of 2.0% for controls]. However, the difference was not significant, a fact that may also be attributed to the small number of analysed trials. Similarly, no difference was found in hospitalizations (NNT ¼ 105 patients, risk for controls patients¼ 2%) Notably, mortality data were reported in only 4 of the 11 included studies. No deaths occurred. Regarding the safety outcomes, no difference was found between patients treated with NIs versus those treated with placebo.
Previous meta-analyses focused mainly on the impact of NIs on time to resolution of influenza symptoms and highlighted the scarcity of data regarding influenza complications. 11, 12, 29 Specifically, a meta-analysis evaluating NIs for prevention and treatment of influenza in healthy adults appeared recently in the literature, 8 while our study was under peer review. This meta-analysis was an update of a relevant Cochrane review, 30 concluding that oseltamivir reduces pneumonia, lower respiratory tract complications, hospital admissions and antibiotic usage in patients with influenza, based on the findings of a single meta-analysis 31 that combined data from published and unpublished studies. In their updated review, the study authors re-evaluated the quality of the unpublished data and they selected to limit their analysis to published data, which however were regarded as insufficient to answer this specific clinical question. In our methodology, we have excluded the study involving mixed studies from our meta-analysis.
Influenza has significant morbidity and mortality and also attracts media attention due to the risk of an epidemic or pandemic. 32 It is associated with augmented utilization of health services 33 and increased economic costs, either direct or indirect. 34, 35 The literature provides evidence that NIs can reduce the severity and the duration (up to 1.5 days in otherwise healthy patients, Heterogeneity: τ 2 = 0.06; χ 2 = 13.89, df = 6(P = 0.03); I 2 = 57% Test for overall effect: Z = 2.38 (P = 0.02) Heterogeneity: τ 2 = 0.00; χ 2 = 1.59, df = 3(P = 0.66); I 2 = 0% Test for overall effect: Z = 4.17 (P < 0.0001) Figure 2 . Total influenza-related complications in otherwise healthy patients, as well as in high-risk patients with laboratory-confirmed influenza, that were treated with neuraminidase inhibitors compared with placebo. The vertical line denotes no difference between the compared treatment groups. Pooled risk ratios (95% CI) are shown by diamond shapes. 95% CIs are shown by horizontal lines. Squares indicate point estimates; the size of the squares denotes the weight that each individual study has in the meta-analysis.
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Systematic review and up to 2.5 days in high-risk patients) of influenza symptoms. 11, 12, 29, 36 Several studies have also focused on the evaluation of the safety profile of NIs, since oseltamivir treatment has been associated with neuropsychiatric adverse events. 34, 37 In our study we focused on influenza complications and mortality directly caused by influenza or triggered by influenza.
According to our findings, oseltamivir was associated with significantly fewer influenza complications, whereas a trend in favour of zanamivir treatment was observed. Similarly, in the sensitivity analysis regarding paediatric and adult trials, NIs were found to be effective in reducing total influenza complications. Moreover, NIs had more benefit in high-risk patients compared with otherwise healthy patients. A trend in favour of treatment with NIs was also obvious regarding additional antibiotic treatment. Recent studies also showed that zanamivir resulted in a reduction of antibiotics used for influenza complications. 38, 39 This issue is of major importance considering the alarmingly increasing rates of antimicrobial resistance observed worldwide, 40, 41 as well as the adverse events of antibiotics. 
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Heterogeneity: τ 2 = 0.05; χ 2 = 10.48, df = 5 (P = 0.06); I 2 = 52% Test for overall effect: Z = 1.84 (P = 0.07) 
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In our meta-analysis, NIs appeared to have a safety profile comparable to that of placebo. However, considerable heterogeneity regarding the evaluated adverse events was observed among the included trials. The method of collecting and reporting adverse events was also either inadequately or not described, a fact that may have possibly influenced our findings. 42 Even though oseltamivir has been previously associated with neuropsychiatric adverse events in children, 37, 43 none of the included trials evaluated the occurrence of such events. However, data provided from post-marketing studies are encouraging, reporting low percentages (0.7% and 1.3%) of serious adverse events for different dosages of oseltamivir. 44 Similarly low percentages were reported for zanamivir. 45 Late complications, such as secondary bacterial pneumonia or ischaemic events, account for a considerable proportion of fatalities in seasonal influenza. Influenza is among the top 10 leading causes of death in the USA. 46 However, no deaths were reported in the analysed trials (enrolling 5140 patients in total). An explanation may be that participants in RCTs have to meet an excessive number of inclusion criteria; however, highrisk patients constituted a considerable proportion (19.5%) of the included patients. In addition, patients participating in clinical trials may tend to have better outcomes than patients encountered in general practice. 47 Our study has limitations that should be considered. First, considerable heterogeneity regarding the study populations and the administered antiviral agents was observed among the included studies. In order to take account of this issue we performed sensitivity analyses. Data regarding the incidence of individual influenza complications were also scarce, possibly accounting for the non-significant differences observed in the respective comparisons. Moreover, even though a considerable proportion of the enrolled patients had confirmed influenza infection, data regarding the specific subtypes of influenza viruses and the respective outcomes were rarely reported. Consequently, we were precluded from assessing the effectiveness of NIs with regard to this factor. 
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Publication and language biases may also have influenced our findings, whereas the use of the Jadad score as a method of assessment of the methodological quality of the included trials may raise considerations. Specifically, even though the majority of the included trials were reported to have a doubleblind design, detailed information regarding allocation concealment was scarce. Furthermore, one small open-label study was included. 24 This may have potentially resulted in an exaggeration of the evaluated intervention effect. 48 However, no substantial differences were observed in the exploratory analyses when excluding this specific study. Additionally, given that the maximum duration of the included trials was 28 days, the observed withdrawal rates were relatively high. Finally, one should also bear in mind that resistance to NIs has been reported in cases of seasonal influenza. 49, 50 Combinations of NIs or combinations of NIs with adamantanes and/or ribavirin have been suggested as a treatment option for such cases. 51 Susceptibility to NIs varies in regard to different influenza viruses. Complications of seasonal influenza also seem to differ from those of pandemic influenza. In the current 2009 pandemic influenza A (H1N1)v, most of the critically ill patients had primary viral pneumonia and had received targeted therapy with a median delay in oseltamivir .6 days after influenza onset. 52 This delay may be crucial for the outcome of this specific infection. Our current findings suggest that prompt antiviral treatment is safe and has potential advantages in seasonal influenza.
Taking all the above into consideration, NIs seem to be effective in reducing influenza complications in both low-and highrisk patients, while they also seem to have an acceptable safety profile. However, RCTs focusing on the effectiveness of NIs in reducing influenza-related complications, providing separate data for mild complications (such as acute otitis media and pharyngitis) and more serious complications (such as pneumonia), are needed. Moreover, the methodology of recording and reporting of adverse events, either total or drug related, should not be subject to bias. Finally, given that mortality, either directly attributed to or triggered by influenza, is considerable, reporting of mortality data in relevant RCTs is a necessity. Heterogeneity: τ 2 = 0.00; χ 2 = 0.22, df = 1 (P = 0.64); I 2 = 0% Test for overall effect: Z = 3.19 (P = 0.001) Heterogeneity: τ 2 = 0.12; χ 2 = 16.85, df = 6 (P = 0.010); I 2 = 64% Test for overall effect: Z = 2.21 (P = 0.03) Figure 7 . Total adverse events, nausea or vomiting, and diarrhoea occurring in patients treated with neuraminidase inhibitors compared with placebo. The vertical line denotes no difference between the compared treatment groups. Pooled risk ratios (95% CI) are shown by diamond shapes. 95% CIs are shown by horizontal lines. Squares indicate point estimates; the size of the squares denotes the weight that each individual study has in the meta-analysis.
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